

COMPOUNDED DRUG TESTING REPORT

In 2003 the Board initiated a program to test drug preparations compounded by pharmacies. All preparations are tested for potency and, if applicable, sterility and endotoxins. The tables listed below are for the fiscal year ending June 30, 2009.

DOSAGE FORM	TESTS PERFORMED
Capsule	49
Inhalation solution	1
Injection	3
I.V. solution	4
Irrigation solution	1
Oral solution	4
Oral suspension	161
Oral syrup	1
Powder	2
Suppository	2
Transdermal	11
Tablet	2
Troche	1

TEST RESULTS	TESTS PERFORMED	PERCENTAGE
Satisfactory	214	88.4%
Unsatisfactory	28	11.6%
Total	242	100%

All unsatisfactory results were related to potency failures. An acceptable potency range is considered +/- 10% of the expected potency, unless a U.S.P. monograph states a different range for a specific preparation. Failing potency results ranged from 0.0% to 145.2%. Pharmacies are notified of unsatisfactory results and asked to complete a quality assurance review of their compounding practices and provide a corrective action plan.

DRUGS WITH UNSATISFACTORY RESULTS
Amitriptyline oral suspension
Atenolol oral suspension
Azathioprine oral suspension
Biest capsules
Biest/Progesterone capsules
Butalbital/APAP/Ergotamine capsules
Clonazepam oral suspension
Captopril oral suspension
DES capsules
DHEA capsules
Lansoprazole oral suspension
Metronidazole oral suspension
Omeprazole oral suspension
Oxytocin/Lactated Ringers IV solution
Progesterone capsules
Progesterone transdermal
Triest/Progesterone capsules
Vancomycin oral suspension